Once-Yearly Zoledronic Acid in Older Men Compared with Women with Recent Hip Fracture

Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival

(2010) P. N. Kannegaard et al.   AGE AND AGEING

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study

(2010) Eric S Orwoll et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Oral bisphosphonates are associated with reduced mortality after hip fracture

(2010) L. A. Beaupre et al.   OSTEOPOROSIS INTERNATIONAL

Anti-Fracture Efficacy of Risedronic Acid in Men

(2009) Zhao-Ming Zhong et al.   CLINICAL DRUG INVESTIGATION

Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women

(2009) Dana Bliuc   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Potential mediators of the mortality reduction with zoledronic acid after hip fracture

(2009) Cathleen S Colón-Emeric et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

(2009) David M Reid et al.   LANCET

Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double-Blind, Multicenter Study

(2008) Steven Boonen et al.   JOURNAL OF BONE AND MINERAL RESEARCH